引用本文:袁 亮,李正维,李靖年.骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸的疗效分析[J].大连医科大学学报,2016,38(1):56-59.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 次   下载 本文二维码信息
码上扫一扫!
分享到: 微信 更多
骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸的疗效分析
袁 亮, 李正维, 李靖年
大连医科大学附属第二医院 脊柱科,辽宁 大连 116027
摘要:
目的 探讨骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸的临床疗效。 方法 将82例骨质疏松性椎体压缩性骨折患者分为两组,分别为经皮椎体后凸成形术(PKP)组和PKP+唑来膦酸组,唑来膦酸治疗后1周及12个月对两组进行随访,并根据疼痛视觉模拟评分(VAS)、骨密度对治疗效果进行评价。 结果 唑来膦酸治疗后1周,PKP+唑来膦酸组VAS评分(3.35±0.81)与PKP组(3.28±0.78)比较,差异无显著性意义(P>0.05);治疗后12个月,PKP+唑来膦酸组VAS评分明显低于PKP组(P<0.05)。PKP组治疗后股骨近端骨密度(BMD)值与治疗前比较差异无显著性意义(P>0.05),PKP+唑来膦酸组治疗后BMD较治疗前明显提高(P<0.05);PKP+唑来膦酸组治疗后BMD与PKP组比较明显增高,差异有显著性意义(P<0.05)。 结论 骨质疏松性骨折经皮椎体后凸成形术后应用唑来膦酸能明显降低腰背部疼痛,提高骨密度,并能遏制骨质疏松症的进一步发展
关键词:  唑来膦酸  经皮椎体成形术  骨质疏松性骨折
DOI:10.11724/jdmu.2016.01.14
分类号:R745
基金项目:
Efficacy analysis of zoledronic acid after percutaneous kyphoplasty for osteoporotic vertebral compression fractures
YUAN Liang, LI Zheng-wei, LI Jing-nian
Department of Orthopedics, the Second Affiliated Hospital of Dalian Medical University, Dalian 116027,China
Abstract:
Objective To investigate the clinical effects of zoledronic acid after percutaneous kyphoplasty for osteoporotic vertebral compression fractures.  Methods Eighty-two patients with osteoporotic vertebral compression fractures were randomly divided into 2 groups: the group given percutaneous kyphoplasty (PKP),and the group given PKP+zoledronic acid. All patients were followed up at 1 week and 12 month and were evaluated according to the VAS pain score standard and bone mineral density (BMD)measurement.  Results At the first week after therapy, the VAS score in the group given PKP+zoledronic acid was 3.35±0.81,which was similar to that in the group given PKP (3.28±0.78), P>0.05. At the 12th month after therapy, the VAS score in the group given PKP+zoledronic acid were significantly lower than that in the group given PKP(P<0.05).The BMD in group given PKP showed no significant difference before and after the therapy (P>0.05),while the BMD in group given PKP+zoledronic acid after the therapy was significantly higher compared with that before the therapy (P<0.05). There was significant difference in BMD between group given PKP+zoledronic acid and group given PKP after the therapy (P<0.05).  Conclusion Application of zoledronic acid after PKP could obviously alleviate pain of the osteoporotic vertebral compression fractures, improve the bone mineral density, and prevent further development of osteoporosis.
Key words:  zoledronic acid  percutaneous kyphoplasty  osteoporotic vertebral fractures